Multilineage Cytopenias, Not Neutropenia Alone, Are Driving Interest in Trilaciclib for ES-SCLC

This article is part 2 of a 2-part series from a Case-Based Roundtable® event. Read part 1.

Neutropenia tends to dominate conversations about chemotherapy-induced myelosuppression, but anemia and thrombocytopenia carry their own burden in extensive-stage small cell lung cancer (ES-SCLC), and the tools available to manage them—erythropoiesis-stimulating agents (ESAs), transfusion, dose reduction—are reactive by design. A case in which all 3 lineages fail in sequence forces a different question: whether a single multilineage agent might prevent the cascade altogether rather than treating each complication as it arrives.

In a virtual Case-Based Roundtable event for oncologists in the Chicago area, Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology and director of clinical research at Dana-Farber Cancer Institute, used a case of sequential anemia and thrombocytopenia to walk participants through pooled data on trilaciclib (Cosela), a CDK4/6 inhibitor that protects multiple hematopoietic lineages simultaneously. Where the group's first case centered on neutropenia and sepsis, this case tested whether oncologists would extend their thinking about supportive care beyond growth factor and toward broader, upfront protection.

The discussion centered on a 63-year-old man on first-line carboplatin, etoposide, and atezolizumab (Tecentriq) who developed extreme fatigue and dizziness before his second cycle, with hemoglobin falling from 12.3 g/dL at baseline to 8 g/dL. A workup ruled out gastrointestinal bleeding, hemolysis, and nutritional deficiency, and his anemia was attributed to chemotherapy. Therapy was delayed a week, and he resumed with a carboplatin dose reduction; after that cycle his hemoglobin fell further to 7.5 g/dL, requiring a red blood cell transfusion. By cycle 4 he developed grade 4 thrombocytopenia with uncontrollable nosebleeds, was hospitalized for a platelet transfusion, and had treatment held for 3 weeks.

Several participants said the case felt familiar. Neil Dalal, DO, noted that some patients run consistently low platelet counts and get treated through it, in part because there's no growth factor analog for thrombocytopenia the way there is for neutropenia or anemia. Nandini Kalakota, MD, said she has used thrombopoietin receptor agonists off label in select patients with chronic, treatment-limiting thrombocytopenia to keep them on cytotoxic therapy, dosing weekly and targeting a platelet count in the 70,000 to 80,000/mcL range rather than full normalization—an approach she said she's used only a handful of times given how difficult these agents are to get approved for solid tumors. Mohamad K. Khasawneh, MD, added that anemia and renal impairment often travel together in this population, making an agent that addresses both lineages at once more appealing than stacking an ESA on top of granulocyte colony-stimulating factor (G-CSF) and absorbing the added thromboembolic risk.

Rotow presented a pooled analysis of trilaciclib across 3 randomized phase 2 studies—G1T28-02 (NCT02499770), G1T28-03 (NCT02514447), and G1T28-05 (NCT03041311)—which showed reductions not just in neutropenia but in grade 3/4 anemia and grade 3/4 thrombocytopenia relative to placebo, along with fewer red blood cell transfusions after the induction phase and fewer chemotherapy dose reductions and delays across all 3 lineages.¹ Quality-of-life measures trended better with trilaciclib than placebo, and time to deterioration on several domains favored the trilaciclib arm. Overall survival and progression-free survival did not differ significantly between arms.

That multilineage signal reframed the conversation. Asked what they would do differently knowing this patient's full course, most participants pointed to upfront trilaciclib rather than any single reactive fix; one oncologist specifically wished for earlier iron supplementation in addition. Sangeetha Nimmagadda, MD, pushed back on the overall framing, noting that without a clear overall survival benefit, the agent's value has to rest on something else entirely—quality of life, fewer hospitalizations, or preserved dose intensity—and that the group hadn't settled on which of those should carry the most weight.

Rotow then posed a parallel, prospective case: a 68-year-old man with hypertension and hyperlipidemia, ECOG performance status of 1, starting frontline carboplatin, etoposide, and atezolizumab with no other complicating factors. Asked whether they would offer trilaciclib to this relatively fit patient before any cytopenia had occurred, most participants said yes—a notable shift from the hesitation expressed earlier in the discussion about insurance access and unproven cost-effectiveness. Several said the retrospective case had been more persuasive than the clinical trial data alone, since it illustrated concretely what a multilineage cascade looks like in practice rather than as an abstract set of trial percentages.

The remaining friction was practical rather than clinical. Participants again pointed to insurance and logistical barriers—delayed authorization, the need for a dedicated infusion visit before chemotherapy, and the absence of a clear pathway for rapid first-cycle access—as the main obstacles to acting on their stated willingness to use the drug. Kalakota suggested that building trilaciclib directly into institutional treatment pathways, the way G-CSF is already built into regimen order sets, would close much of that gap by making multilineage prophylaxis the default rather than an opt-in addition requiring separate justification.

Polling results from the live event reflected that shift toward multilineage prophylaxis.

REFERENCE

1. Liu Y, Wu L, Huang D, et al. Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies. Cancer Treat Res Commun. 2024;42:100869. doi: 10.1016/j.ctarc.2025.100869. Epub 2025 Jan 10. PMID: 39823755.